HY-075

HY-075 is an oral liquid cardiovascular drug candidate being developed by Hyloris for use in coronary heart disease in the United States, positioned as a reformulated, patient-friendly oral solution of an existing active ingredient rather than a novel molecular entity. Public information indicates it is part of Hyloris’s lifecycle management portfolio of improved formulations but does not disclose the specific active pharmaceutical ingredient, detailed mechanism of action, or clinical-stage data, suggesting that HY-075 is intended as a differentiated dosage form of a known coronary therapy to address unmet needs in administration or convenience rather than to introduce a new pharmacology.